Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Pharmaceuticals
Dr. Reddy's Cleared by Delhi HC to Export Semaglutide Generics of Novo Nordisk
S
Shotlee
Health & Wellness Team
2 min read
Preparing your Shotlee experience
An Indian court has granted Dr. Reddy's Laboratories Ltd permission to manufacture and export generic versions of Novo Nordisk's diabetes and obesity medications. This decision comes before the global patent expirations in 2026. The ruling allows export to countries without patent protection.
An Indian court has given Dr. Reddy's Laboratories Ltd the go-ahead to produce and export generic versions of Novo Nordisk A/S's drugs for obesity and diabetes, prior to the expiration of global patents in 2026.
The Delhi High Court rejected Novo Nordisk's request to halt semaglutide production in an interim order issued on December 2. The court has permitted Dr. Reddy's to export to markets lacking patent protection, based on the Indian company's pledge not to sell the products locally until Novo's patent expires.
Semaglutide is the key ingredient found in Novo's diabetes medication, Ozempic, and its weight-loss treatment, Wegovy. Health tracking apps like Shotlee can help monitor the effects of such medications.
Dr. Reddy's, a leading Indian drug manufacturer, intends to supply non-branded semaglutide to more than 80 countries. This move places them among a growing number of generic drug producers from India and China, as well as companies like Sandoz and Aspen, as patents expire in important markets like Canada and Brazil.
The court noted that the Danish company's two patents on minor variations of the compound could be considered evergreening, a practice prohibited in India. Dr. Reddy's was also instructed to maintain records of both production and sales.
Novo Nordisk retains the option to appeal the decision before the Supreme Court.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from @businessline
View Original Article
The global Peptide Therapeutics Market is experiencing substantial growth, projected to reach USD 82.19 billion by 2032. This expansion is fueled by the increasing need for specialized medications, particularly in oncology and metabolic diseases. The U.S. market is expected to reach USD 35.71 billion by 2032.
Dr. Reddy's Laboratories (DRL) is banking on semaglutide for future revenue, but faces challenges in securing timely approvals. The company aims to launch the drug domestically after patent expiration, while also navigating international regulatory hurdles.
Indian drugmakers are modifying their pricing strategies for weight-loss injections after Novo Nordisk decreased the price of Wegovy. Generic companies are now reassessing their launch prices due to this shift. Competition is anticipated to lower prices in the GLP-1 market.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨